SHIFT Newsroom · GLOBAL
CagriSema trial: what the REDEFINE 9 paper adds
The paper gives a fuller account of a trial of two lower doses of the investigational injection, including an analysis that accounts for people stopping treatment.
In the 68-week randomised trial, adults with overweight or obesity without diabetes received weekly injections of CagriSema or placebo. Estimated average weight loss in an analysis that counted people regardless of whether they stopped treatment or used rescue treatment was 19.4% and 18.6% at the two doses, versus 4.6% with placebo. Digestive side effects were the most common. Side effects led about 3% and 5% of the two treatment groups to stop permanently, versus about 5% on placebo.
SHIFT’s take: The study compared each dose with placebo. It cannot tell us which dose works better or establish UK access.
Sources: Trial report, published online 14 November00275-5) · Novo results and methods · Original congress slides · Trial registry.
SHIFT’s take
A separate SHIFT interpretation has not been added to this report.
Known facts
- Estimated average weight loss in an analysis that counted people regardless of whether they stopped treatment or used rescue treatment was 19.4% and 18.6% at the two doses, versus 4.6% with placebo.